Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the anti-PD-1 monoclonal antibody sintilimab and the modified FOLFIRINOX (mFOLFIRINOX) chemotherapy regimen. Sintilimab is a biologic immunotherapy that targets the PD-1 receptor to enhance the immune system's ability to detect and destroy cancer cells. The mFOLFIRINOX component is a multi-agent chemotherapy regimen comprising fluorouracil, leucovorin, irinotecan, and oxaliplatin. This combination is being investigated by researchers at Zhejiang University as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), aiming to leverage the synergistic effects of immune checkpoint inhibition and cytotoxic chemotherapy to improve clinical outcomes in this aggressive malignancy.
- Other names
- sintilimab + modified FOLFIRINOXAnti-PD-1 Antibody plus mFOLFIRINOXAnti-PD1 Antibody plus mFOLFIRINOXAnti-PD 1 Antibody plus mFOLFIRINOXCombination drug-Zhejiang University-pancreatic ductal adenocarcinoma
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sintilimab + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + mFOLFIRINOX.